This is a working overview of Water activity, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory and labeling frameworks vary by country. In the United States, whey protein hydrolysate may be regulated as a food ingredient or a dietary supplement ingredient depending on intended use. In the European Union, it falls under general food law, with additional rules for infant formula and foods for special medical purposes. A claim of hypoallergenicity is not established by hydrolysis alone and generally requires clinical evidence. Open questions remain about how degree of hydrolysis relates to bitterness, nitrogen absorption, and residual allergenicity across different products and processing methods.
Quality control for whey protein hydrolysate combines compositional and molecular tests. Protein content is measured by Kjeldahl or Dumas nitrogen determination. Moisture, ash, fat, and lactose are checked with standard food methods. The degree of hydrolysis is estimated by TNBS, OPA, or pH-stat procedures that quantify free amino groups or released protons. Molecular weight distribution is examined by size-exclusion chromatography or SDS-PAGE. These tests describe average peptide size rather than exact peptide sequences, and results depend on standards and calibration.
Whey protein hydrolysate appears in foods, infant formula, sports nutrition, and specialized clinical nutrition. Its production can reduce viscosity and improve heat stability compared with intact whey protein. Bitterness is common because short hydrophobic peptides can activate bitter taste receptors. The ingredient is not the same as free amino acids; it remains a mixture of peptides of different lengths. Composition varies by supplier, enzyme, and process, so two hydrolysates with the same protein content may behave differently in a formulation.
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with enzymes or, less often, acid or heat to break peptide bonds. The starting material is typically sweet whey or acid whey from cheese making, first concentrated and dried into whey protein concentrate or isolate. Hydrolysis shortens long protein chains into smaller peptides, changing functional properties such as solubility, viscosity, and foam formation. The resulting powder contains peptides, residual intact protein, moisture, minerals, and variable amounts of lactose and fat depending on the starting material.
Enzymatic hydrolysis usually uses proteases from microbial, plant, or animal sources. The enzyme choice, pH, temperature, and reaction time determine which peptide bonds are cleaved and the final peptide profile. After hydrolysis, the enzyme is inactivated by heat, and the mixture is clarified, filtered, concentrated, and spray-dried. Manufacturers may use ultrafiltration to remove larger peptides or minerals. The degree of hydrolysis, often reported as a percentage, describes the proportion of peptide bonds broken. A higher degree generally means shorter peptides, but it does not by itself define taste, allergenicity, or biological activity.
| Property | Value | Notes |
|---|---|---|
| Protein determination | Kjeldahl nitrogen × 6.38 | Dumas combustion also used |
| Degree of hydrolysis | TNBS, OPA, or pH-stat | Results method-dependent |
| Molecular weight distribution | SEC-HPLC or SDS-PAGE | Reports ranges, not sequences |
| Residual lactose | Enzymatic or HPLC | Relevant for low-lactose products |
| Microbiological limit | Total plate count < 10^4 CFU/g | Typical internal specification, varies |
Regulatory status differs by country and intended use. In many jurisdictions, whey protein hydrolysate is regulated as a food ingredient, while specific infant formula or medical food uses may require additional review. Labeling rules govern protein content claims, allergen statements, and terms such as partially hydrolyzed or extensively hydrolyzed. Analytical methods for degree of hydrolysis are not fully standardized, so values can depend on the assay. This variability makes direct comparison between products difficult unless the method and reference material are stated.
Quality control for whey protein hydrolysate begins with specification of protein, moisture, ash, fat, lactose, and degree of hydrolysis, while molecular weight distribution is measured by size-exclusion chromatography or electrophoresis. Free amino acid content can be quantified by amino acid analysis. Microbial limits, heavy metals, and residual enzyme activity are also monitored. Because hydrolysis conditions influence batch consistency, manufacturers validate processes and test each lot against release criteria. Sampling plans and reference standards help compare results across laboratories.
Storage stability depends on moisture, temperature, oxygen, and packaging, and hydrolysates are hygroscopic and can cake when exposed to humid air. Maillard reactions between peptides and residual lactose can cause browning and flavor changes during warm storage, while lipid oxidation may develop if residual fat is present. Cool, dry conditions and sealed containers slow these reactions. Shelf-life studies typically monitor moisture, color, solubility, molecular weight profile, and microbial counts over time. Accelerated tests estimate stability, but real-time data remain the reference for shelf-life assignment.
Regulatory treatment of whey protein hydrolysate depends on the country and intended use. In many jurisdictions it is regulated as a food ingredient or food for special dietary use, not as a drug. Labeling rules govern allergen statements, protein content claims, and ingredient names. Some markets have specific rules for infant formula ingredients, where hydrolysates may be used for particular dietary purposes. Regulations generally focus on safety, truthful labeling, and manufacturing standards rather than on therapeutic effects. Scientific questions about specific peptide activities remain an active area of research rather than a settled regulatory category.
Whey protein hydrolysate powders are hygroscopic and can absorb moisture from air. Moisture uptake may lead to caking, reduced flowability, and gradual peptide degradation. Manufacturers typically specify cool, dry storage and sealed packaging to limit these changes. Water activity, rather than water content alone, is often monitored because it better predicts microbial and chemical stability. High temperatures can accelerate Maillard reactions between peptides and residual sugars, altering color and flavor. Exact shelf lives depend on formulation, packaging, and initial moisture, so they are usually determined by product-specific stability testing.
Analytical testing for whey protein hydrolysate focuses on peptide size distribution, degree of hydrolysis, protein content, moisture, ash, and microbiological quality. Size-exclusion chromatography and mass spectrometry can characterize peptide profiles, while Kjeldahl or combustion methods estimate total nitrogen and protein. Amino acid analysis quantifies free and total amino acids. Because peptide mixtures are complex, no single method captures every property, and results can vary between laboratories. Standardized methods and reference materials help improve comparability, but full sequence-level characterization remains uncommon in routine quality control.
Hydrolysates are generally stable as dry powders but can absorb moisture and undergo browning during warm storage. The bitter taste of some hydrolysates arises from hydrophobic peptides exposed by cleavage, and it varies with enzyme choice and degree of hydrolysis. Reduced allergenicity is sometimes claimed, but residual IgE-binding peptides may remain, especially in partial hydrolysates. Regulatory frameworks treat extensively hydrolyzed and partially hydrolyzed products differently, and labeling rules vary by country. More research is needed on how specific peptide profiles relate to clinical outcomes.
Commercial production begins with whey protein concentrate or isolate dissolved in water. A protease is added under controlled pH and temperature, and the reaction is stopped by heat or pH adjustment once a target degree of hydrolysis is reached. Membrane filtration, often ultrafiltration or diafiltration, removes enzymes and small solutes while retaining peptides. The liquid is then concentrated and spray-dried into a powder. Each step influences peptide length, mineral content, and flavor.
Quality control focuses on degree of hydrolysis, molecular weight distribution, protein content, moisture, ash, and microbial limits. Degree of hydrolysis is commonly calculated from the number of cleaved peptide bonds relative to total peptide bonds. Size-exclusion chromatography and mass spectrometry can describe peptide size ranges, while amino acid analysis quantifies composition. Standard methods from dairy science organizations are often used, though no single method captures every functional property. Results are therefore reported alongside processing conditions.
RBR and HBR were defined in the initial release of the DisplayPort standard, version 1.0 HBR2 was introduced in version 1.2 HBR3 was introduced in version 1.3 UHBR10, UHBR13.5, and UHBR20 were introduced in version 2.0 However, transmission mode support is not necessarily dictated by a device's claimed "DisplayPort version number". For example, older versions of the DisplayPort Marketing Guidelines allowed a device to be labeled as "DisplayPort 1.2" if it supported the MST feature, even if it didn't support the HBR2 transmission mode. Newer versions of the guidelines have removed this clause, and currently (as of the June 2018 revision) there are no guidelines on the usage of DisplayPort version numbers in products. DisplayPort "version numbers" are therefore not a reliable indication of what transmission speeds a device can support. In addition, individual devices may have their own arbitrary limitations beyond transmission speed. For example, NVIDIA Kepler GK104 GPUs (such as the GeForce GTX 680 and 770) support "DisplayPort 1.2" with the HBR2 transmission mode, but are limited to 540 Mpx/s, only 3⁄4 of the maximum possible with HBR2. Consequently, certain devices may have limitations that differ from those listed in the following tables. To support a particular format, the source and display devices must both support the required transmission mode, and the DisplayPort cable must also be capable of handling the required bandwidth of that transmission mode. (See: Cables and connectors)
== Concepts and complications == Compounds precipitate from a solution when its concentration exceeds its solubility, i.e. the solution is supersaturated. Supersaturation can arise from temperature changes, solvent evaporation, or by mixing solvents. Precipitation occurs more rapidly from a strongly supersaturated solution.
In mouse leukemia model driven by fusion oncoprotein, condensate arrest suppressed target gene expression and inhibited cell proliferation. These findings provide mechanistic support for the functional relevance of the condensate microenvironment. Together, these studies establish the condensate microenvironment as a key mechanism in the regulation of biochemical specificity, localization, and activity within cells.
=== 1986 === 31 July Turbo: Once Around the Block, about British motor racing; the Ferrari F1/86 and the Imola Circuit in Emilia-Romagna in northern Italy, and Tifosi spectators; the 1984 British Grand Prix at Brands Hatch; the Motronic engine control units of Robert Bosch GmbH; Keith Duckworth, known for the Cosworth DFV, and Michael Kranefuss, head of Ford Motor Sport; Walter Hayes of Ford of Europe; Renault began turbocharged motor racing vehicles at the 1977 British Grand Prix on 16 July 1977, with the Renault RS01; Cosworth in Northampton; Beatrice Foods of the US, and Ford form an agreement in 1985, with Australian Alan Jones, with designer John Baldwin; the 1981 Italian Grand Prix and crash of John Watson; the assembled Cosworth GBA V6 engine is tested at Northampton. Produced by Patrick Uden, made by Uden Associates.
== Structure and function == The formyl peptide receptor (FPR) belongs to the class of receptors possessing seven hydrophobic transmembrane domains. The conformation of the FPR is stabilized by several interactions. These include potential salt bridge formation between Arg84-Arg205, Lys85-Arg205, and Lys85-Asp284 which help determine the three-dimensional structure of transmembrane domains, as well as positively charged residues (Arg, Lys) which interact with negatively charged phosphates. Furthermore, residue Arg163 may interact with the ligand binding pocket of the second extracellular loop of the FPR. With respect to binding of the formyl Met-Leu-Phe peptide, there are additional potential interactions which include hydrogen bonding interactions between Arg84 and Lys85 of the first extracellular loop and the N-formyl group of the ligand as well as the peptide backbone of formyl Met-Leu-Phe which can form similar interactions. The formyl-Met moiety of the ligand was shown to form disulfide bridges with Cys residues, and an interaction with Arg163 was also demonstrated. (It is important to mention that some interaction which stabilize the conformation of the receptor may also influence ligand-binding.) Some oligopeptides were also described as characteristic constituents linked to Asn-s of the extracellular N terminal part and to the ligand binding pocket of the second extracellular loop. These components can also determine or make more specific the ligand-receptor interaction.
Sources: en.wikipedia.org
===== Stimulants ===== Cocaine and methamphetamine exposure induce epigenetic modifications of the OPRK1 and PDYN loci through both histone remodeling and DNA methylation pathways. Acute cocaine and methamphetamine increase histone H4 acetylation and histone acetyltransferase (HAT) activity in the striatum, facilitating increased PDYN and OPRK1 transcription that initiates dynorphin-mediated counter-inhibition of dopamine release. This acute epigenetic activation could be interpreted as a compensatory mechanism attempting to restore dopaminergic homeostasis during drug-induced dopaminergic overstimulation. In chronic context cocaine and methamphetamine exposure reverse this epigenetic profile through increased DNA methyltransferase (DNMT) activity and histone deacetylase (HDAC)-mediated repression of plasticity genes, including decreased OPRK1 transcription. Epigenetic silencing of adaptability genes consolidates compulsive drug-seeking behaviour whilst simultaneously dysregulating the KOR-mediated feedback system, facilitating withdrawal-related dysphoria and relapse vulnerability.
Dibenzoylmorphine is an opioid analogue that is a derivative of morphine. It was developed in the early 1900s after first having been synthesised in 1875 in the UK by the CR Alders Wright organisation at Bayer, along with various other esters of morphine. It was never used medically, instead being widely sold as one of the first "designer drugs" for around five years following the introduction of the first international restrictions on the sale of heroin in 1925. It is described as being virtually identical to heroin and morphine in its effects, and consequently was itself banned internationally in 1930 by the Health Committee of the League of Nations, in order to prevent its sale as an unscheduled alternative to diacetylmorphine. However, it still continues to occasionally be encountered as a result of home manufacture from morphine by drug users. It is produced in the same fashion as other esters of morphine—treating morphine with an acid anhydride (or some acids or other relatives of acids like acetyl chloride) to get a mono-, di-, tri-, or tetra-ester. Specifically, the original 1875 synthesis was effected by boiling morphine for 2 hours in benzoic anhydride at 130 °C, as was heroin made by using acetic anhydride.
For people with MASLD who have undifferentiated cirrhosis, the APWG recommends an investigation to determine the cause of the cirrhosis as well as the person's liver function and whether they have portal hypertension.
=== Brand names === Trazodone has been marketed under a large number of brand names throughout the world. Major brand names include Desyrel (worldwide), Donaren (Brazil), Molipaxin (Ireland, United Kingdom), Oleptro (United States), Trazorel (Canada), and Trittico (worldwide).
AAS users tend to research the drugs they are taking more than other controlled-substance users; however, the major sources consulted by steroid users include friends, non-medical handbooks, internet-based forums, blogs, and fitness magazines, which can provide questionable or inaccurate information. AAS users tend to be unhappy with the portrayal of AAS as deadly in the media and in politics. According to one study, AAS users also distrust their physicians and in the sample 56% had not disclosed their AAS use to their physicians. Another 2007 study had similar findings, showing that, while 66% of individuals using AAS for non-medical purposes were willing to seek medical supervision for their steroid use, 58% lacked trust in their physicians, 92% felt that the medical community's knowledge of non-medical AAS use was lacking, and 99% felt that the public has an exaggerated view of the side-effects of AAS use. A recent study has also shown that long term AAS users were more likely to have symptoms of muscle dysmorphia and also showed stronger endorsement of more conventional male roles. A recent study in the Journal of Health Psychology showed that many users believed that steroids used in moderation were safe. AAS have been used by men and women in many different kinds of professional sports to attain a competitive edge or to assist in recovery from injury. These sports include bodybuilding, weightlifting, shot put and other track and field, cycling, baseball, wrestling, mixed martial arts, boxing, football, and cricket.
Sources: en.wikipedia.org
It is often estimated by TNBS, OPA, or pH-stat methods that quantify free amino groups or released protons. Values depend on assay conditions, protein standard, and calculation method. No single universal protocol exists for all products.
It shows the relative amounts of peptides in different size ranges, commonly by size-exclusion chromatography or SDS-PAGE. A lower average weight indicates more extensive hydrolysis. It does not identify specific peptide sequences or biological effects.
No. Immunoassays can measure residual protein or specific whey proteins, but hypoallergenicity requires clinical evaluation. Hydrolysis may reduce IgE-binding, yet some peptides can remain reactive. Label claims are regulated separately from analytical results.
It is whey protein that has been partially broken down into smaller peptides through hydrolysis. The powder still contains a mixture of peptides, residual protein, minerals, and other whey components. It is used as a food ingredient rather than a single pure compound.